January 18, 2024 - Neurochase

Spark Therapeutics Enters Into Strategic Collaboration with Neurochase

DuncanarioNCH January 18, 2024 No Comments

Original Article: Global News Wire Spark Therapeutics Enters Into Strategic Collaboration with Neurochase for Use of Proprietary Delivery Technology for CNS Disorders PHILADELPHIA, Jan. 27, 2023 (GLOBE NEWSWIRE) — Spark [...]

Novel Gene Therapy for Motor Neurone Disease (MND) & Parkinson’s (PD)

DuncanarioNCH January 18, 2024 No Comments

Innervate Therapeutics is a biotechnology company focused on developing glial cell -derived neurotrophic factor (GDNF) gene therapies to achieve neuro-restoration and neuroprotection in diseases including PD and MND. GDNF, a [...]

Brain Tumor Therapy – A New Indication For Hamlet Pharma

DuncanarioNCH January 18, 2024 No Comments

Original Article Today, Hamlet Pharma signed a joint development agreement with Neurochase Limited, founded by Professor Steven Gill, a world leading expert in the area of neurosurgery, to develop novel [...]

AviadoBio Announces Formation of Scientific Advisory Board

DuncanarioNCH January 18, 2024 No Comments

AviadoBio, a pioneering, pre-clinical stage, gene therapy company focused on developing and delivering transformative medicines for people with neurodegenerative disorders, announces that it has established a Scientific Advisory Board (SAB) [...]

CombiGene and Neurochase Preclinical Study

DuncanarioNCH January 18, 2024 No Comments

CombiGene’s and Neurochase’s preclinical study provides valuable information for the upcoming long-term studies in toxicology and biodistribution STOCKHOLM — On June 28, 2021, CombiGene (“CombiGene”, “the Company”) announced that the [...]

Day: January 18, 2024

Spark Therapeutics Enters Into Strategic Collaboration with Neurochase

Novel Gene Therapy for Motor Neurone Disease (MND) & Parkinson’s (PD)

Brain Tumor Therapy – A New Indication For Hamlet Pharma

AviadoBio Announces Formation of Scientific Advisory Board

CombiGene and Neurochase Preclinical Study